Big news: The JNJ vaccine results of 44,000 Phase 3 trial, a single dose. Overall 66% efficacy, with the contrast of 72% in US but 57% in South Africa, confirming immune escape/resistance of B.1.351 variant seen by Novavax pic.twitter.com/0WfXgkZVos— Eric Topol (@EricTopol) January 29, 2021
Big news: The JNJ vaccine results of 44,000 Phase 3 trial, a single dose. Overall 66% efficacy, with the contrast of 72% in US but 57% in South Africa, confirming immune escape/resistance of B.1.351 variant seen by Novavax pic.twitter.com/0WfXgkZVos
This news is certainly welcome, clearly fulfills FDA threshold and adds to the vaccine tool chest. It is a clear drop down from the 2-dose mRNA efficacyhttps://t.co/Pgkdm1ggIg @matthewherper @statnews— Eric Topol (@EricTopol) January 29, 2021
This news is certainly welcome, clearly fulfills FDA threshold and adds to the vaccine tool chest. It is a clear drop down from the 2-dose mRNA efficacyhttps://t.co/Pgkdm1ggIg @matthewherper @statnews
01-29-2021, 07:47 AM
